Which FDA‑approved non‑stimulant can be added to Qelbree (viloxazine) for the treatment of attention‑deficit/hyperactivity disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Extended-Release Guanfacine or Clonidine Can Be Added to Qelbree

The FDA-approved non-stimulant medications that can be added to Qelbree (viloxazine) for ADHD treatment are extended-release guanfacine and extended-release clonidine, both alpha-2 agonists approved specifically for use as adjunctive therapy to other ADHD medications. 1

Regulatory Approval for Combination Therapy

Both guanfacine ER and clonidine ER are explicitly FDA-approved for use either as monotherapy OR as adjunctive therapy to stimulants in ADHD treatment 1. While the evidence base primarily documents their combination with stimulants, their approval language permits adjunctive use with other ADHD medications, which would include viloxazine.

Practical Considerations for Each Option

Guanfacine Extended-Release

  • Dosing: Weight-based at approximately 0.1 mg/kg once daily
  • Available strengths: 1,2,3, and 4 mg tablets
  • Onset: 2-4 weeks for full therapeutic effect
  • Key advantage: Higher specificity for alpha-2A receptors may result in less sedation compared to clonidine 1

Clonidine Extended-Release

  • Dosing: Start 0.1 mg at bedtime, can increase to twice daily, maximum 0.4 mg/day
  • Available strengths: 0.1 and 0.2 mg tablets, plus transdermal patches (0.1,0.2,0.3 mg)
  • Onset: 2-4 weeks for full therapeutic effect
  • Note: Approximately 10 times more potent than guanfacine but less receptor-specific 1

Mechanism and Rationale

This combination strategy leverages complementary mechanisms:

  • Viloxazine: Selective norepinephrine reuptake inhibitor with additional serotonergic modulation 2
  • Alpha-2 agonists: Enhance prefrontal cortex noradrenergic neurotransmission through postsynaptic alpha-2 receptor stimulation, strengthening top-down attention and working memory regulation 1

Critical Safety Monitoring

When combining these agents, monitor for:

Cardiovascular effects: Both viloxazine and alpha-2 agonists can affect blood pressure and heart rate. Check BP and HR before starting combination therapy and regularly thereafter 3, 1

Additive sedation: The most common overlapping adverse effect. Both drug classes cause somnolence/fatigue 1, 3. Consider evening dosing of the alpha-2 agonist to minimize daytime sedation.

Discontinuation precautions: Alpha-2 agonists require gradual tapering to avoid rebound hypertension 1

Important Caveats

  • Atomoxetine is NOT recommended for combination with viloxazine despite both being norepinephrine reuptake inhibitors, as this would create redundant mechanisms and potentially excessive noradrenergic effects
  • The evidence base for combining viloxazine specifically with alpha-2 agonists is limited, as most combination studies evaluated alpha-2 agonists with stimulants 1
  • European approval for guanfacine restricts its use to cases where stimulants are unsuitable, though US approval is broader 1
  • Effect sizes for non-stimulant combinations are generally smaller than stimulant-based regimens 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.